Microbiotica and Genentech Partner to Study Microbiome Biomarkers and New IBD Therapies
News
Microbiotica, a company spun out of the Wellcome Sanger Institute, recently established a multiyear collaboration agreement with Genentech to discover, develop, and commercialize biomarkers, targets, and therapies for inflammatory bowel disease (IBD). ... Read more